AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on October 5, 2022. The company is incorporated in Delaware and trades on The NASDAQ Stock Market LLC under the symbol "AYTU". The report addresses a specific event regarding the availability of its pharmaceutical product.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific disclosure event rather than a periodic financial statement.
Material Changes and Events
- Regulation FD Disclosure (Item 7.01): On October 5, 2022, the company announced the continuing availability of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (CII).
- Market Context: This announcement was made in response to numerous reported supply disruptions affecting generic Adderall XR (mixed salts amphetamine) extended-release capsules (CII), which are used for the treatment of attention deficit hyperactivity disorder (ADHD).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the context of the supply chain disruptions in the ADHD treatment market. The primary focus is the confirmation of product availability.
Key Facts for Investor Verification
- Verify the current market share and sales impact of Adzenys XR-ODT relative to generic Adderall XR.
- Confirm the duration and severity of the reported supply disruptions for generic Adderall XR.
- Review the attached press release (Exhibit 99.1) for detailed commercial implications.